Several small-molecule inhibitors against Slack have been reported, providing informative starting points for drug development efforts with KCNT1-related epilepsy (Cole et al., 2020; Griffin et al., 2021; Spitznagel et al., 2020). Here, KCNT1 is linked to epilepsy.